## The Helmet Sign: Physiologic Radioactive Accumulation After <sup>131</sup>I Therapy—A Case Report

Lorraine Ash, DO1; Bohdan Bybel, MD2; Donald Neumann, MD2; and Wendy Beebe, CNMT2

<sup>1</sup>Department of Diagnostic Radiology, Cleveland Clinic Foundation, Cleveland, Ohio; and <sup>2</sup>Department of Molecular and Functional Imaging, Cleveland Clinic Foundation, Cleveland, Ohio

After <sup>131</sup>I radioablative treatment, a 51-y-old woman underwent whole-body <sup>131</sup>I scanning, which revealed intense uptake along the periphery of the skull. The patient disclosed that she had not washed her hair because she had obtained a new hairstyle between the <sup>131</sup>I treatment and the scan. The intense uptake along the periphery of the skull represented radioactive physiologic accumulation at the patient's scalp. *Key Words:* thyroid cancer; radionuclide imaging; contamination artifact; physiologic variant

J Nucl Med Technol 2004; 32:164-165


The specificity of <sup>131</sup>I whole-body scans for detecting residual or recurrent local and metastatic disease is generally reported to be greater than 90% (*I*). However, in failing to recognize physiologic accumulation from perspiration, as in the following case, and other potential contamination artifacts and physiologic variants, the specificity is further compromised and often leads to unwarranted examinations and additional radiation exposure.

## **CASE REPORT**

A 51-y-old African-American woman with a history of metastatic papillary thyroid cancer had undergone surgical resection of the tumor, external-beam radiation therapy for residual local disease, and treatment with 2 radioablative doses of <sup>131</sup>I. The patient had been doing well, and her thyroglobulin levels had been stable. Because of a recent thyroglobulin increase, a whole-body <sup>131</sup>I scan was ordered to identify any residual disease. Tracer uptake in the neck suggested local recurrence (Fig. 1). Subsequently, radioablative treatment with 5.55 GBq of <sup>131</sup>I was given.

Ten days after treatment, the patient returned for a wholebody scan to better identify any other recurrences or meta-

E-mail: bybelb@ccf.org



**FIGURE 1.** Anterior view of skull from whole-body <sup>131</sup>I scan. Uptake is present in the region of the thyroid bed.

static disease. In addition to uptake at the thyroid bed, increased uptake along the periphery of the skull was present (Fig. 2). Upon questioning, the patient revealed that between the <sup>131</sup>I treatment and the scan, she had not washed her hair because she wished to preserve the hair extensions she had placed. The patient stated that rather than washing her hair, which would disturb the hair extensions weaved into her own hair, she applied a petroleum-based jelly to the scalp to prevent drying. Presumably, this application caused perspiration to collect along her scalp within the hairline and produced the intense uptake of tracer seen along the periphery of the skull.

## DISCUSSION

The scope of false-positive findings after radioiodine treatment has been well documented (I-I2). Such findings are primarily physiologic, being secondary to uptake in tissues that can concentrate  $^{131}$ I but do not retain it in organic form (II). Diffuse hepatic uptake due to the metabolism of radioiodinated thyroid hormones in the liver, as

For correspondence or reprints contact: Bohdan Bybel, MD, Department of Molecular and Functional Imaging, Cleveland Clinic Foundation, 9500 Euclid Gb3, Cleveland, OH 44195.



**FIGURE 2.** Anterior view of skull after <sup>131</sup>I treatment. Diffuse uptake is present along the periphery of the skull.

well as salivary and intestinal activity, is commonly seen (11). Contamination of the patient's personal items, such as perspiration on jewelry or nasal secretions on a handkerchief, is reported less often but represents a very real pitfall for accurate interpretation of whole-body  $^{131}$ I images (1,3–12). In our case, the patient history, the knowledge of  $^{131}$ I artifacts, and the atypical location and distribution of the uptake all served to identify the abnormal tracer uptake as a physiologic variant.

## **REFERENCES**

- McDougall IR. Whole-body scintigraphy with radioioidine-131: a comprehensive list of false-positives with some examples. Clin Nucl Med. 1995; 20:869-875.
- Bakheet SM, Hammami MM. False-positive thyroid cancer metastasis on whole-body radioiodine scanning due to retained radioactivity in the oesophagus. Eur J Nucl Med. 1993;20:415–419.
- Bakheet SM, Hammami MM. Spurious thyroid cancer bone metastases on radioiodine scan due to external contamination. Eur J Radiol. 1993;16: 239–242.
- Boxen I, Zong MZ. Nasal secretion of iodine-131. Clin Nucl Med. 1990; 15:610-611.
- Bybel B, Beebe W, Kim BY, et al. Contamination of a bracelet following iodine-131 therapy: a case report. J Nucl Med Technol. 2000;28:257–258.
- Dick C, Mudun A, Alazraki NP. False-positive I-131 images mimicking thyroid cancer metastasis: the nose ring sign. Clin Nucl Med. 1995;20:876– 877
- Greenler DP, Klein HA. The scope of false-positive iodine-131 images for thyroid carcinoma. Clin Nucl Med. 1989;14:111–117.
- Grigsby P. Cost minimization analysis and utility of pretreatment and posttreatment total body iodine-131 scan in patients with thyroid carcinoma. *Cancer.* 1998;82:931–935.
- Park HM, Tarver RD, Schauwecker DS, et al. Spurious thyroid cancer metastasis: saliva contamination artifact in high dose iodine-131 metastases survey. J Nucl Med. 1986;27:634–636.
- Pochis WT, Krasnow AZ, Isitman AT, et al. The radioactive handkerchief sign: a contamination artifact in I-131 imaging for metastatic thyroid carcinoma. Clin Nucl Med. 1990;15:491–494.
- Shapiro B, Rufini V, Jarwan A, et al. Artifacts, anatomic and physiological variants, and unrelated diseases that might cause false-positive whole-body I-131 scan in patients with thyroid cancer. Semin Nucl Med. 2000;30:115– 132.
- Sutter CW, Masilungan BG, Stadalnik RC. False-positive results of I-131 whole-body scan in patients with thyroid cancer. Semin Nucl Med. 1995; 25:279–282.